Aim: To investigate the cost-effectiveness of a pharmacogenetic dosing algorithm versus a clinical dosing algorithm for coumarin anticoagulants in The Netherlands. Materials & methods: A decision-analytic Markov model was used to analyze the cost-effectiveness of pharmacogenetic dosing of phenprocoumon and acenocoumarol versus clinical dosing. Results: Pharmacogenetic dosing increased costs by €33 and quality-adjusted life-years (QALYs) by 0.001. The incremental cost-effectiveness ratios were €28,349 and €24,427 per QALY gained for phenprocoumon and acenocoumarol, respectively. At a willingness-to-pay threshold of €20,000 per QALY, the pharmacogenetic dosing algorithm was not likely to be cost effective compared with the clinical dosing algorithm. Conclusion: Pharmacogenetic dosing improves health only slightly when compared with clinical dosing. However, availability of low-cost genotyping would make it a cost-effective option. Original submitted 20 August 2014; Revision submitted 15 October 201.

, , , ,,
Institute for Medical Technology Assessment (iMTA)

Verhoef, T., Redekop, K., De Boer, A., & Maitland-van der Zee, A.-H. (2015). Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in the Netherlands. Pharmacogenomics, 16(2), 101–114. doi:10.2217/pgs.14.149